

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE SIX MONTHS ENDED 30 JUNE 2023

On 6 July 2023, Dong-E-E-Jiao released its results estimate for the six months ended 30 June 2023.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) is a company incorporated in the People’s Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 8.86% of its equity interests by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and approximately 23.14% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 21.96% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 6 July 2023, Dong-E-E-Jiao released its results estimate for the six months ended 30 June 2023, in which, it announced that the net profit attributable to the shareholders of Dong-E-E-Jiao for the six months ended 30 June 2023 is estimated to range from approximately RMB510 million to RMB550 million, representing an increase between approximately 65% and 78% as compared to that of approximately RMB308.2624 million for the same period last year, net profit excluding non-recurring gain or loss is estimated to range from approximately RMB470 million to RMB510 million, representing an increase between approximately 76% and 91% as compared to that of approximately RMB266.8777 million for the same period last year, and basic earnings per share is estimated to range from approximately RMB0.79 per share to approximately RMB0.85 per share (as compared to that of approximately RMB0.4787 per share for the same period last year) (the “**Dong-E-E-Jiao Results Estimate**”).

The main reasons for the change in results are set forth as follows:

1. Dong-E-E-Jiao has solidly implemented the “14th Five-Year Plan” strategic planning, focusing on the key theme of “growth and efficiency”, practising the “four reshaping” in great depth, and adhering to the dual growth model of “pharmaceuticals” and “health consumer products”. It continues to promote its position as a top-tier brand of “Zi Bu Guo Bao Dong-E-E-Jiao”, comprehensively rejuvenating and renewing the brand, and accumulating brand potential. Adhering to a consumer-centric approach, Dong-E-E-Jiao continues to strengthen its core fundamental businesses. The market share of E-Jiao blocks has significantly increased, the strategy for the broad category of compound E-Jiao paste products continues to gain momentum, and the “Taohuajie” E-Jiao cake products achieves rapid growth through all channels, with steadily improving operating performance.
2. In the future, Dong-E-E-Jiao will continue to integrate into the national big health development strategy, focusing on consumers and adhering to the “higher, deeper, and more solid” standards. It will continue to promote the “four reshaping” and consolidate its position as a top-tier brand of “Zi Bu Guo Bao Dong-E-E-Jiao”. It will continue to deepen the business model with dual drivers of “pharmaceuticals” and “health consumer products”, vigorously implement the research and development planning with “one center” and “three highlands”, and explore new categories, new products, new effects, and new target groups. Focusing on big health industry, Dong-E-E-Jiao will expand into new tracks, seek new opportunities for external development, and strive to become the most trusted leader in nourishment and health among consumers.

The Dong-E-E-Jiao Results Estimate was prepared in accordance with the PRC Generally Accepted Accounting Principles and has not been audited or reviewed. For the details of financial data, those to be disclosed in the interim report for the six months ended 30 June 2023 to be issued by Dong-E-E-Jiao shall prevail.

The financial information in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational of financial status of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Beijing, 7 July 2023

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong and Mr. Tao Ran as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.